Two new cyclic bisbibenzyl derivatives from Hebertus dicranus  

作　　者：XU Chang-Long WANG Jin-Xin LI Hui-Liang 

机构地区：[1]School of Pharmacy and Life Science, Jiujiang University [2]School of Pharmacy, Second Military Medical University

出　　处：《Chinese Journal of Natural Medicines》2016年第6期457-461,共5页中国天然药物（英文版）

基　　金：supported by program NCET Foundation,National Natural Science Foundation of China(Nos.81230090,81102335,and 81473109);Shanghai Leading Academic Discipline Project(B906);Key Laboratory of Drug Research for Special Environments,PLA,Shanghai Engineering Research Center for the Preparation of Bioactive Natural Products(10DZ2251300);the Scientific Foundation of Shanghai China(Nos.12401900801,13401900101);National Major Project of China(No.2011ZX09307-002-03);the National Key Technology R&D Program of China(No.2012BAI29B06);the National Natural Science Foundation of China(No.21161009);the Natural Science Foundation of Jiangxi Province(No.20132BAB203004)

摘　　要：In the present study, two new cyclic bisbibenzyls(1, 2) co-occuring with a known compound, isoplagiochins C(3) were isolated from Hebertus dicranus. The structures were determined mainly by extensive 1D and 2D NMR experiments, and the absolute configurations of 1 and 2 were established by the circular dichroism spectrum. Furthermore, all these three rare compounds were tested in vitro for inhibitory activity against the growth of human cancer cell lines(A549, HCT116, MDA-MB-231, and BEL7404) by the MTT assay, and compound 2 exhibited moderately inhibitory activity with IC50 values ranging from 13.89 to 31.62 ?mol·L-1. In conclusion, our results provided a basis for future development and modification of these compounds for cancer therapy.In the present study, two new cyclic bisbibenzyls（1, 2） co-occuring with a known compound, isoplagiochins C（3） were isolated from Hebertus dicranus. The structures were determined mainly by extensive 1D and 2D NMR experiments, and the absolute configurations of 1 and 2 were established by the circular dichroism spectrum. Furthermore, all these three rare compounds were tested in vitro for inhibitory activity against the growth of human cancer cell lines（A549, HCT116, MDA-MB-231, and BEL7404） by the MTT assay, and compound 2 exhibited moderately inhibitory activity with IC50 values ranging from 13.89 to 31.62 ？mol·L-1. In conclusion, our results provided a basis for future development and modification of these compounds for cancer therapy.

关 键 词：Hebertus dicranus Cyclic bisbibenzyl Circular dichroism spectrum 

分 类 号：R284.1[医药卫生—中药学]